Rivastigmine in Mild Alzheimer's Disease, FMRI Study

Kuopio University Hospital20 enrolled

Overview

The purpose of the study is to investigate the effect of rivastigmine given as an acute dose compared to placebo and after 1 month chronic dosing on fMRI response during a face recognition task. Furthermore, the aim is to investigate whether fMRI response is correlated with long term treatment effect at 6 months and 12 months.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

QUADRUPLE

Enrollment

Conditions

Alzheimer' Disease

Interventions

rivastigmineDRUG

Acute dose 3 mg or placebo. Thereafter 1.5 mg x 2 ad 30 days and thereafter increasing the dose upto 4.5 mg x 2 according to instructions.

Eligibility

Sex: ALLMin age: 55 YearsMax age: 85 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Probable Alzheimer's disease according to the NINCDS-ADRDA criteria * mild disease, CDR 1 * the clinician is planning to start anticholinesterase treatment Exclusion Criteria: * cognitive impairment for other reason than Alzheimer's disease * severe depression * other unstable physical disease * medal in body prevention MRI examination, claustrophobia * cardiac pacemaker * other significant neurologic or psychiatric disease * contraindication for anticholinesterase treatment

Locations (1)

Kuopio University Hospital

Kuopio, Finland

Outcomes

Primary Outcomes

FMRI response in face recognition task

Time frame: at baseline and at 1 mo

Secondary Outcomes

treatment response measured by ADAS-cog

Time frame: at 6 month and 1 year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.